Physician profile
Tatiana K Clark
NPI 1891159752
$34,103.17
in general payments reported to CMS, 2019-2025
67 companies · $6,019 in 2025
The $6,019 reported for 2025 was more than what 99% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $6,258 · 2022: $4,769 · 2023: $7,608 · 2024: $9,449 · 2025: $6,019.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $19K · Travel and Lodging: $3,756 · Education: $268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $19,051.64 |
| Travel and Lodging | $3,756.27 |
| Education | $268.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $6,459.40 | 2021-2025 | Infinity, Proclaim |
| Abbvie INC. | $3,229.21 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,909.48 | 2021-2025 | Ajovy, Austedo Xr, Austedo |
| Emd Serono, INC. | $1,627.52 | 2021-2025 | Mavenclad, Mavenclad |
| Boston Scientific Corporation | $1,397.15 | 2022-2024 | Vercise |
| Medtronic, INC. | $1,234.21 | 2022-2025 | Percept Pc Brainsense, Activa Pc |
| Biohaven Pharmaceutical Holding Company Ltd. | $1,118.19 | 2022 | |
| Pfizer INC. | $1,115.35 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $967.25 | 2021-2025 | |
| Eisai INC. | $917.44 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $852.37 | 2021 | |
| Ucb, INC. | $816.56 | 2021-2025 | Zilbrysq, Nayzilam, Briviact |
| Biogen, INC. | $733.31 | 2021-2025 | Vumerity, Tysabri |
| Ge Healthcare | $696.93 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $655.83 | 2021-2025 | Xywav, Epidiolex |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $654.91 | 2021-2025 | |
| Lilly USA, LLC | $623.08 | 2021-2025 | Emgality, Amyvid, Reyvow |
| Lundbeck LLC | $606.91 | 2021-2025 | Vyepti, Rexulti |
| Alexion Pharmaceuticals, INC. | $600.65 | 2021-2025 | Ultomiris, Soliris |
| Amgen INC. | $591.02 | 2021-2025 | Uplizna |
| Neurocrine Biosciences, INC. | $502.43 | 2021-2025 | Ingrezza, Ongentys |
| Otsuka America Pharmaceutical, INC. | $458.31 | 2023-2025 | Rexulti, Nuedexta |
| Celgene Corporation | $433.43 | 2022-2025 | Zeposia |
| Acadia Pharmaceuticals INC | $413.43 | 2021-2025 | Nuplazid |
| Sk Life Science, INC. | $385.05 | 2021-2025 | Xcopri |
| Axsome Therapeutics, INC. | $370.32 | 2024-2025 | Symbravo, Sunosi |
| Genentech USA, INC. | $351.89 | 2021-2025 | Ocrevus, Ocrevus Zunovo |
| Argenx US, INC. | $334.09 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Allergan, INC. | $317.42 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $261.66 | 2021-2025 | Rytary, Ongentys, Crexont |
| Acorda Therapeutics, INC | $249.28 | 2021-2024 | Inbrija |
| Takeda Pharmaceuticals U.S.A., INC. | $234.69 | 2024-2025 | Hyqvia |
| Harmony Biosciences LLC | $220.63 | 2021-2023 | Wakix |
| Kyowa Kirin, INC. | $218.26 | 2022-2024 | Nourianz |
| Avanir Pharmaceuticals, INC. | $214.08 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $186.67 | 2021-2024 | Zeposia |
| Mdd US Operations, LLC | $172.56 | 2021-2025 | Qelbree, Gocovri |
| Corium, LLC | $170.71 | 2022-2023 | Azstarys, Adlarity |
| Neurelis, INC. | $142.31 | 2021-2025 | Valtoco |
| Merz Pharmaceuticals, LLC | $137.48 | 2023-2025 | Xeomin, Inbrija |
| Sunovion Pharmaceuticals INC. | $132.39 | 2021 | |
| Sanofi-Aventis U.S. LLC | $128.93 | 2021 | |
| Novo Nordisk INC | $124.55 | 2023 | Wegovy |
| Vanda Pharmaceuticals INC. | $112.89 | 2021-2025 | Ponvory |
| Janssen Pharmaceuticals, INC | $94.55 | 2021-2022 | |
| Avion Pharmaceuticals | $93.65 | 2021-2022 | |
| Tanabe Pharma America, INC. | $93.47 | 2024-2025 | Radicava |
| Grifols USA, LLC | $85.85 | 2022-2025 | Gamunex-C |
| Supernus Pharmaceuticals, INC. | $78.38 | 2021-2022 | |
| Horizon Therapeutics Plc | $75.03 | 2022-2023 | Uplizna |
| Alnylam Pharmaceuticals INC. | $64.52 | 2023-2024 | Onpattro |
| Csl Behring | $57.51 | 2021-2023 | Hizentra |
| Livanova USA, INC. | $51.05 | 2024-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Sumitomo Pharma America, INC. | $48.46 | 2023-2024 | Aptiom |
| Astrazeneca Pharmaceuticals Lp | $31.11 | 2021-2022 | |
| Averitas Pharma INC. | $29.96 | 2023 | Qutenza |
| Upsher-Smith Laboratories LLC | $29.05 | 2022 | |
| Banner Life Sciences, LLC | $24.61 | 2022 | |
| Impel Pharmaceuticals LLC | $24.29 | 2025 | Trudhesa |
| Azurity Pharmaceuticals, INC. | $22.50 | 2025 | Horizant |
| Janssen Biotech, INC. | $20.90 | 2025 | |
| Inspire Medical Systems, INC. | $20.06 | 2024 | Inspire |
| Cycle Pharmaceuticals INC | $19.77 | 2025 | Tascenso Odt, Bafiertam |
| Adamas Pharmaceuticals, INC. | $16.07 | 2021 | |
| Zogenix INC. | $15.00 | 2021 | |
| Xeris Pharmaceuticals, INC. | $14.76 | 2024 | Keveyis |
| Currax Pharmaceuticals LLC | $12.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tatiana Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.